U.S. markets closed

Marinus Pharmaceuticals, Inc. (MRNS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
15.26+0.54 (+3.67%)
At close: 4:00PM EDT

15.36 +0.10 (0.63%)
After hours: 4:11PM EDT

Marinus Pharmaceuticals, Inc.

5 Radnor Corporate Center
Suite 500 100 Matsonford Road
Radnor, PA 19087
United States
484 801 4670
http://www.marinuspharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees65

Key Executives

NameTitlePayExercisedYear Born
Dr. Scott N. BraunsteinCEO, Pres & Director898.88kN/A1963
Mr. Edward F. Smith CPAConsultant570.09kN/A1971
Dr. Joseph Hulihan M.D.Chief Medical Officer488.87kN/A1956
Mr. Steven E. Pfanstiel C.M.A., M.B.A.CFO & TreasurerN/AN/A1973
Ms. Sasha Damouni EllisVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Ms. Martha E. ManningVP, Gen. Counsel & Sec.N/AN/A1955
Mr. Thomas J. LyonsVP of Corp., Bus. Devel. & Commercial PlanningN/AN/AN/A
Ms. Lisa LejuwaanVP of SalesN/AN/AN/A
Ms. Rose McKinleyVP of HR & Organizational Devel.N/AN/AN/A
Dr. Alex AimettiHead of Scientific AffairsN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Marinus Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing and commercializing therapeutics to treat rare seizure disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in formulations for two routes, including intravenous (IV) and oral for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ganaxolone product candidate, acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for status epilepticus, cyclin dependent kinase like 5 deficiency disorder, PCDH19-related epilepsy, tuberous sclerosis complex, and postpartum depression. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc. The company was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

Corporate Governance

Marinus Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 9. The pillar scores are Audit: 5; Board: 9; Shareholder Rights: 6; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.